Standout Papers

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanc... 2021 2026 2022 2024175
  1. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma (2021)
    David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology

Citation Impact

13 by Nobel laureates 51 standout
Sub-graph 1 of 24

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
1 intermediate paper

Works of Marek Ziobro being referenced

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
2021 Standout

Author Peers

Author Oncology Molecular Biology PRM Last Decade Papers Cites
Marek Ziobro 263 183 256 42 430
Ryu Maeda 15 586 11 14 712
Dirk Bröll 3 17 10 403
Sven Mothes 3 17 236
Beth A. Lalonde 2 729 2 8 751
Erhard Neher 1 17 50 636

All Works

Loading papers...

Rankless by CCL
2026